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Definitions of endoscopic, transmural and 
histological healing
The management of inflammatory bowel disease 
(IBD), a chronic and disabling disease, is still 
challenging despite the fact that many new drugs 
have been developed, with more in the pipeline, 
to achieve tight control of inflammation and 
improve outcomes of the disease. A symptoms-
based treatment is generally suboptimal, as there 
is wide dissociation between symptoms and 
inflammation. Hence, we have moved from a 
purely clinical assessment, to a multi-target 
approach involving endoscopic mucosal healing 
(MH), histological healing, cross-sectional imag-
ing and transmural healing (TH), and surrogate 
markers of inflammation, providing the basis for 
the concept of ‘treat to target’.1–3
An emerging concept is ‘deep remission’, a pro-
found remission without clinical symptoms and 
biological activity, with complete MH, usually 
assessed by colonoscopy in ulcerative colitis (UC) 
and by ileocolonoscopy in Crohn’s disease (CD), 
and disappearance of histological inflammatory 
changes (histological healing). To date there is not 
a clear and validated definition of deep remission in 
IBD.4–6 Current studies have also included, in this 
definition, non-invasive markers of inflammation 
such as C reactive protein (CRP), faecal calprotec-
tin (FC) and radiological parameters that are being 
considered as new potential tools for objective 
assessment of all bowel layers, that is, TH in par-
ticular in CD.4,7 Importantly, the achievement of 
deep remission should alter biological processes of 
mucosal inflammation and prevent progressive and 
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permanent structural damage typical of IBD 
patients. Achieving such ‘deep’ remission is an 
aspirational challenge, feasible in only a minority of 
IBD patients. Therefore, defining very strict end-
points of intestinal healing will have failed many of 
the current targeted therapies and challenge future 
drug development programs.4,8,9
Endoscopic mucosal healing in ulcerative colitis
In the context of IBD, the term MH generally 
refers to endoscopic assessment of disease activ-
ity, though endoscopic healing may be a more 
specific term.
The International Organization for the Study of 
Inflammatory Bowel Disease (IOIBD) defined 
MH in UC as the absence of friability, blood, ero-
sions and ulcers in all visualized segments of the 
colonic mucosa.3 Therefore this corresponds to 
Mayo Endoscopic Score (MES) of 0 rather than 
MES 1, as MES 1 generally has worse disease 
course than MES 0. It is a topic of intense debate 
whether MH involves histological healing in UC. 
Increasing evidence has shown that endoscopic 
healing does not necessarily mean histological 
healing and the presence of subtle patchy inflam-
mation, even in an endoscopically quiescent dis-
ease, could be associated with adverse outcomes.10 
At present, histological remission is not consid-
ered a primary endpoint in clinical trials due to a 
lack of standardization and validation, but in UC 
it is increasing being used as a secondary outcome 
measure either independently or in combination 
with endoscopic healing. MES is commonly used 
as a major secondary endpoint in clinical trials 
and in clinical practice and is also integrated into 
the Mayo Clinical Disease Activity Score, while 
UC Endoscopic Index of Severity (UCEIS) is 
used less commonly, as its advantage over MES is 
not clear.11
Endoscopic mucosal healing and transmural 
healing in Crohn’s disease
MH in CD generally represents endoscopic MH. 
Currently, there is no validated score or definition 
of MH in CD.12 Several studies have defined MH 
in CD as the resolution of visible mucosal ulcers.3 
The EXTEND (Extend the Safety and Efficacy 
of Adalimumab through Endoscopic Healing) 
trial was the first placebo-controlled endoscopy 
trial that evaluated the effects of adalimumab on 
MH in CD patients (n = 129).13 This study and 
subsequent accumulating data have shown that 
the achievement of MH is associated with better 
outcomes with reduced risk of relapse, long-term 
corticosteroid-free remission and less surgery and 
hospitalization.14–19
In a systematic review and meta-analysis of 12 
prospective cohorts, including 673 active CD 
patients, achieving endoscopic remission (or 
MH) on the first post-treatment endoscopy was 
associated with a higher likelihood of long-term 
clinical remission ⩾50 weeks [pooled odds ratio 
(OR) 2.80, 95% confidence interval (CI), 1.91–
4.10], maintenance of MH (14.30, 95% CI, 
5.57–36.74) and lower risk of CD-related surgery 
(2.22, 95% CI, 0.86–5.69).20
However, it is not clear if endoscopic MH and 
histological remission reflect the healing of the 
entire bowel wall layers. The resolution of 
inflammation assessed by cross-sectional imag-
ing has been recognized as a valid target in 
patients with CD according to the Selecting 
Therapeutic Targets in Inflammatory Bowel 
Disease (STRIDE) initiative by IOIBD.3
Consequently, TH is another dimension that is 
gradually being appreciated. This means the nor-
malization of bowel wall thickening assessed by 
cross-sectional imaging: magnetic resonance 
enterography (MRE), ultrasound (US) and com-
puted tomography enterography (CTE). Many 
studies have compared, head to head, the accu-
racy of these techniques, and have concluded that 
they are similar in assessing inflammation and 
damage.21
In a multicentre prospective study involving 284 
patients, Taylor and colleagues have compared 
the diagnostic accuracy of MRE and US for the 
presence, extent and activity of CD. Both reached 
high accuracy for detecting small bowel CD, but 
MRE had a higher sensitivity and specificity in 
terms of presence and extension of small bowel 
disease.22
Recently, the Image Kids study group has exam-
ined in 151 children the association between MH 
assessed by endoscopy and TH by MRE. In 69% 
of patients there was concordance in terms of 
MH and TH. Interestingly, one-third of patients 
have mucosal inflammation with TH and 6% of 
patients showed MH with active disease detected 
by MRE. It is, however, still difficult to identify 
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whether lesions observed by MRE are an index of 
active disease or of permanent fibrotic damage.23
However, the achievement of TH improves long-
term clinical outcome in respect of MH and his-
tologic healing. Indeed, the study by Fernandes 
and colleagues has shown that patients who have 
achieved TH have less need for surgery, hospitali-
zation and therapy escalation than patients that 
have reached only MH.24
Histological healing in ulcerative colitis
European Crohn’s and Colitis Organisation 
(ECCO) guidelines defined histological healing 
as resolution of crypt architectural distortion and 
inflammatory infiltrate.25 This should mean the 
histological normalization of the bowel mucosa. 
Many histological scoring systems have been pro-
posed, but none of them have clearly defined the 
histological healing or ‘deep’ sustained healing, 
though the newer scores are evolving these 
definitions.12
The most widely used scores for UC are the Riley 
Index and the Geboes Index.
The Riley Index involves acute inflammatory 
infiltrate, crypt abscesses, mucin depletion, epi-
thelial integrity, chronic inflammatory infiltrate 
and crypt architectural abnormalities, each of 
which is graded subjectively on a four-point scale 
and given equal weight.
The Geboes Index Evaluates architectural 
change, lamina propria neutrophils and eosino-
phils, neutrophils in epithelium, crypt destruc-
tion and erosion or ulceration. It was not designed 
to be responsive to change and even if it is rou-
tinely used it is only partially and formally 
validated.12,26
Based on items of the Geboes Index, Mosli and 
colleagues have developed the Robarts 
Histopathology Index (RHI), a new validated 
index comprising chronic inflammatory infiltrate, 
lamina propria neutrophils, neutrophils in the 
epithelium and erosion or ulceration.27
Recently, the Nancy Score has been validated for 
use in clinical practice and clinical trials, showing 
good intraobserver and interobserver reliability 
and good responsiveness. It describes three histo-
logical items – ulceration, acute inflammatory 
infiltrate and chronic inflammatory infiltrate – 
resulting in a five-grade classification.28
Romkens and colleagues reported that there was 
a high interobserver concordance between 
Geboes score, Riley score and the Harpaz Gupta 
Index, a four-point scale including three features: 
cryptitis, ulcers and erosions.29,30 There was a 
poor concordance on UC biopsies between gen-
eral pathologists and gastrointestinal pathologists 
on histological assessment of remission. Histologic 
activity was present in 20–80% of patients with 
MES 0.29
Blanco and colleagues have evaluated the agree-
ment between histological healing and MH. They 
considered, in 34 moderate-to-severe patients, 
the histological response to anti-tumour necrosis 
factor (TNF) therapy with adalimumab at 8 and 
52 weeks. At week 52, 31% of patients had histo-
logical remission (Geboes score < 3.0) and all of 
them had MH, while 61.8% achieved MH (MES 
0–1) at week 52 but only 42.8% of them had his-
tological healing. Of note, the agreement between 
histological remission and MH at week 52 was 
only fair.31
The endoscopic assessment of severe signs of 
inflammation as erosions and ulcers is generally 
agreed upon easily, and histology correlate well 
with MES 2–3, while the main discrepancies 
 concern the evaluation of mild activity, MH and 
histological healing.32,33 It has been generally 
accepted that absence of inflammation is MH; 
however, intestinal healing itself is an active pro-
cess with its own characteristics, such as regener-
ative changes visible at endoscopy.
Several authors have reported different outcomes 
in patients with MES 0 (no mucosal abnormali-
ties) and MES 1 (mild erythema or decreased 
vascular pattern).
In the subgroup analysis of the ACT1 and 2 trials, 
patients with MES 0 were significantly more often 
in corticosteroid-free remission after 1 year of fol-
low up than patients with MES 1 (73% versus 
47%; p < 0.001), while no differences were found 
in the colectomy rate.34
A prospective study by Barreiro-de Acosta and 
colleagues included patients in clinical remission 
with either MES 1 or MES 0 and the risk of 
relapse was significantly higher in patients with 
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MES 1 than those with MES 0 (41.0% versus 
19.3%; p < 0.01).35 Similarly, a retrospective 
study by Carvalho and colleagues including 138 
patients has shown that MES 1 was significantly 
associated with an increased risk of relapse (OR, 
2.89; 95% CI, 1.14–7.36; p = 0.026.).36
The importance of achieving histological remis-
sion was recently demonstrated by a systematic 
review and meta-analysis showing that the inci-
dence of clinical relapse was significantly lower 
among patients with baseline histological remis-
sion than those with histological activity [relative 
risk (RR) = 0.48; 95% CI 0.39–0.60.]37 
Similarly, a prospective observational study 
involved 76 patients affected by UC in clinical 
remission who were followed for 6 months. Among 
them, 46 patients were in endoscopic remission 
(MES ⩽1) and histological remission was observed 
in 31/46 patients. After 1 year the rate of sustained 
clinical remission was significantly higher in 
patients who had been in histological remission 
than among those with histological activity (87.1% 
versus 46.6%, p = 0.006). These data support that 
histological assessment rather than endoscopy 
 better predicts sustained clinical remission.38 
However, the endoscopic assessment was with 
standard-definition white-light endoscopy (WLE).
Bryant and colleagues evaluated the ability of his-
tological remission compared to endoscopic heal-
ing by WLE to predict clinical outcome in 91 UC 
patients followed up over 6 years. The most strik-
ing data is that histological remission, and not 
endoscopic MH, predicted corticosteroid use and 
acute severe colitis requiring hospitalization over 
the 6-year follow-up period.39
Recently, Ozaki and colleagues have confirmed 
the need for histological examination even in 
patients with endoscopically normal mucosa; 194 
UC patients with MH (MES ⩽1) were enrolled 
with a mean follow-up period of 20 months. 
Overall, 34.5% relapsed during the follow-up 
period and mucin depletion was an independent 
risk factor for clinical relapse in these patients 
with endoscopically normal mucosa [hazard ratio, 
2.18 (1.16–5.82); p = 0.03].40
Many studies have examined different histological 
microscopic features able to predict clinical out-
come. Riley and colleagues, in a pioneering study 
including 82 patients with UC in asymptomatic 
and endoscopic remission, have reported a higher 
relapse within 12 months in the presence of an 
acute inflammatory cell infiltrate, crypt abscesses 
and mucin depletion in biopsies.41
Later, Bessissow and colleagues, in a cohort study 
involving 75 patients with normal endoscopy, 
demonstrated that the presence of basal plasma-
cytosis and a Geboes score >3.1 predict clinical 
relapse in patients with complete MH (OR, 5.13; 
95% CI, 1.32–19.99; p = 0.052).42
According to Calafat and colleagues, the presence 
of neutrophils in the epithelium was considered 
as a risk factor for clinical relapse in 113 asympto-
matic patients affected by UC with both clinically 
and endoscopic remission.43
The importance of histology as endpoint has been 
supported by the US Food and Drug Administration 
(FDA). They stated that ‘endoscopy alone (with-
out histology) only provides an assessment of the 
visual appearance of the mucosa’. Thereby the 
definition of MH could not be exhaustive by endo-
scopic findings alone and requires resolution of 
histological inflammation. Currently there are no 
criteria for histological assessment of MH, but the 
FDA encourages and suggests incorporating his-
tology instruments into the definition of MH.44
Since it has been reported that up to 40% of 
patients have persistent histological inflammatory 
activity despite clinical remission and MH, a hot 
topic of discussion, with a consensus among experts 
convened by ECCO, has become exit strategies: 
when is the best time to stop therapies in patients 
with stable clinical and endoscopic remission, con-
sidering the risks and benefits of prolonged treat-
ment?45–47 In future, histological assessment could 
guide our clinical management, for example by 
decreasing or stopping therapy, checking for non-
adherence or optimizing treatment.48
Several studies have showed histological remis-
sion or improvement following therapy.
Magro and colleagues carried out a multicentre, 
single-cohort, open-label, 52-week trial including 
20 moderate–severe bionaive UC patients receiv-
ing intravenous infliximab (5 mg/kg). After 8 weeks 
of treatment the proportion of patients who 
achieved histological remission (Geboes score 
⩽3.0) was 15% compared with 5% at baseline 
and 35% at week 52.49 Similarly, adalimumab was 
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also able to induce histological remission in a con-
siderable proportion of UC patients at week 52 
(26.5%, intention to treat).31 Furthermore, Arijs 
and colleagues have shown that vedolizumab 
induced endoscopic MH in 55% of patients who 
achieved also histological healing with a maximal 
effect seen at week 52.50
It is important to note that in these studies the 
rate of histological healing requires more pro-
longed treatment than clinical or endoscopic 
remission and may occur differentially within 
each segment of the colon or bowel. A possible 
explanation could be the drug mechanisms as 
well as their pharmacokinetic properties that 
relate to histological remission.51
Other complications, such as dysplasia, may be 
influenced by chronicity of inflammation; persis-
tence of histological inflammation can impact on 
the risk of colorectal carcinoma in IBD patients. 
Long-term benefit of histological healing on devel-
opment of colorectal carcinoma was shown by a 
case–control study of 68 UC patients and 136 
controls; a significant correlation between endo-
scopic scores (OR, 2.5; p = 0.001) and histological 
scores (OR, 5.1; p < 0.001) was observed. On 
multivariate analysis, histologic inflammation was 
the only risk factor for development of colorectal 
neoplasia in patients with long-standing, extensive 
UC (p < 0.001).52
A recent meta-analysis by Flores and colleagues 
has shown that the risk of development of colo-
rectal neoplasia was higher in patients with histo-
logical inflammation compared to patients with 
endoscopic MH (OR, 2.6).53
Histological healing in CD
The relationship between histology and endos-
copy in CD may be more complex because of 
patchy and transmural involvement. It is not yet 
clear whether only histological remission by endo-
scopic biopsies could add more practical informa-
tion to manage CD patients or whether having 
persistent transmural inflammation is related to 
development of complications.
Recently, a study by Brennan and colleagues has 
shown the ability of histology (and not endoscopic 
activity) to predict clinical flares at 6, 12 and 
24 months in 62 CD patients undergoing colonos-
copy during clinical remission. Indeed, at month 
12 the rate of flares was 25.5% in patients with his-
tologic activity, compared with only 2.4% of 
patients without histologic activity at baseline.54
Christensen and colleagues, in a retrospective 
analysis of 101 patients affected by CD, have 
examined clinical relapse-free survival and reported 
a fair agreement between mucosal and histologic 
activity. On multivariate analysis, only histologic 
remission was associated with a lower risk of clini-
cal relapse (HR 1.85; 95% CI, 1.00–3.44).55
Further studies are required, especially address-
ing histological scoring systems in CD and patch-
iness of inflammation.
Surrogate markers to predict histological 
healing
The relationship between endoscopy and surro-
gate markers of inflammation is a matter of 
increasing interest and is well studied, but there 
are few data available on their role in predicting 
histological remission.56
Guardiola and colleagues, in a prospective obser-
vational study of 59 patients with UC, evaluated 
the accuracy of FC to identify patients with histo-
logic features of inflammation despite clinical and 
endoscopic remission. The evidence of active his-
tologic inflammation in at least 1 colonic segment 
was found in 30.5% of patients in endoscopic 
remission. A significantly higher median level of 
FC was found in patients with active histologic 
inflammation compared with those without active 
histologic inflammation (p = 0.002). In a multi-
variable analysis, FC is an independent predictor 
of histologic inflammation in patients with endo-
scopic remission.57
Similarly, Magro and colleagues have reported 
that FC and faecal lactoferrin highly correlate 
with histological activity.49 However, more pro-
spective studies and larger sample sizes are needed 
in the future.
Limitation of white-light endoscopy to define 
endoscopic and histological healing
Conventional WLE, although it remains the most 
widely used standard procedure in daily practice, is 
not able to define subtle and mild residual signs of 
inflammation as well as the ‘depth’ of MH relative 
to histology, especially when standard-definition 
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settings or scopes are used. WLE does not give us 
a detailed image of mucosal and especially vascular 
patterns, and its ability is generally restricted to 
assessing acute disease activity and extension. 
Many studies have highlighted that an accurate 
distinction between different grades of inflamma-
tion is crucial to stratify risk of relapse, predict 
clinical outcomes and guide therapeutic manage-
ment. WLE healing may not quite define the sub-
tle changes of inflammation that may relate to 
‘stableness’ of remission and long-term outcomes.
New advanced high-definition (HD) endoscopic 
technologies, optical diagnosis narrow-band imag-
ing (NBI; Olympus Japan), i-scan (Pentax, Japan), 
blue laser image (BLI; Fujifilm, Japan), confocal 
laser endomicroscopy (CLE; Mauna Kea, France), 
EndoCytoscopy (EC; Olympus, Japan) and the 
emerging endoscopic molecular labelling seem to 
give promising results to improve diagnostic accu-
racy in IBD.58 Some are already available in rou-
tine clinical practice and have revolutionized the 
classical definition of MH as these can see almost 
at histology level. A classical description of mucosal 
friability and loss of vascular pattern are no longer 
valid, and a new endoscopic language, including 
crypt architecture, micro-erosions, fine vascular 
changes around the crypts and distinction between 
intramucosal and luminal bleeding, has recently 
been introduced.58,59
In one of the earliest reports, Kudo and colleagues 
focused on the mucosal vascular pattern (MVP) 
in patients with asymptomatic or mildly active 
UC using NBI and HD WLE. Interestingly, they 
have showed that the determination of MVP was 
significantly different between conventional colo-
noscopy and NBI colonoscopy (p = 0.0001). NBI 
yielded a more precise assessment of inflamma-
tion in quiescent UC patients and correlated well 
with histologic items.60
Significant evidence on the potential of NBI as an 
electronic chromoendoscopy technique came 
from a pilot study including 14 IBD patients, con-
ducted by Danese and colleagues. These authors 
reported that areas that appeared normal on WLE 
but altered on NBI had an increased leucocyte 
infiltrate and micro-vessel density as assessed by 
histology.61
The ability of HD colonoscopy to better assess 
inflammation was demonstrated by Iacucci and 
colleagues initially in a retrospective cohort study. 
A total of 78 patients with UC underwent HD 
WLE and HD i-scan. A grading system based on 
mucosal and vascular patterns was designed for 
i-scan. Overall, there was a statistically significant 
correlation between i-scan imaging scores (mucosal 
and vascular patterns) and MES (rs = 0.86; 95% 
CI, 0.79–0.91; p < 0.0001). Interestingly, 30.4% 
patients of with MES 0 on WLE had abnormal 
mucosal pattern and 73.9% had an abnormal vas-
cular pattern. The authors concluded that i-scan 
colonoscopy can improve the detection of subtle 
patchy inflammation in patients with MES 0, 
despite apparently healed mucosa and thus direct 
targeted biopsies.62 This may be especially relevant 
for the patchiness of healing after therapy.
Advanced and novel endoscopy technologies 
to assess mucosal healing
Advanced endoscopic techniques play a potential 
role in the management of IBD as these reduce 
the gap between what we can see during conven-
tional endoscopy and patchy microscopic changes 
of mucosa detected by histology.
Dye chromoendoscopy
Dye chromoendoscopy (DCE) has a stronger 
correlation to histopathology compared with 
WLE to assess mucosal inflammation. The prin-
ciple of DCE is staining mucosa to enhance the 
mucosal surface pattern. In one of the earliest 
prospective randomized trials by Kiesslich, 165 
patients affected by UC were randomized at a 1:1 
ratio to undergo conventional colonoscopy or 
colonoscopy using 0.1% methylene blue. There 
was signiﬁcantly better correlation between the 
endoscopic assessment of degree of inﬂammation 
and the histopathology in the chromoendoscopy 
group compared with the WLE colonoscopy 
group (89% versus 52%; p < 0.0001). Methylene 
blue-aided chromoendoscopy in combination 
with optical magnification seems to be more 
accurate in assessing the degree and extent of 
inflammation compared to standard WLE.63
Ibarra-Palomino and colleagues investigated in 
UC patients the ability of chromoendoscopy with 
methylene blue 0.2% or indigo carmine 0.1% to 
determine extension and severity in relation to 
histopathology, considered as the gold standard. 
The assessment of severity of UC, in particular 
for areas with minimal or silent activity, was 
improved by chromoendoscopy.64 This reflects 
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the limited bandwidth of MES 0–3, especially at 
the lower end of the scale.
Nishio and colleagues, in a prospective trial 
including 113 patients with quiescent UC, ana-
lysed the role of magnification endoscopy using 
methylene blue spray to predict clinical relapse. 
The authors classified the rectal pit pattern 
appearance into four grades according to its 
abnormalities. There was a positive correlation 
between this grading and the degree of histological 
inflammation. Concerning clinical outcome, the 
higher degree of subtle inflammation increased 
the risk of relapse during 12 months of follow up.65
Dye-less chromoendoscopy
The introduction of dye-less chromoendoscopy 
techniques has overcome the potential limita-
tions of DCE; indeed, this technique is simple to 
use by just ‘the push of a button’ and is cost- and 
time-efficient in comparison to DCE. Newly 
emerging generation electronic virtual chro-
moendoscopy (EVC) modalities include: NBI-
near focus (Olympus; Tokyo, Japan), the i-scan 
OE (Pentax; Tokyo, Japan), blue laser image 
(BLI) and linked colour imaging technology 
(LCI; Fujinon, Fujifilm, Tokyo, Japan).59 The 
quality of such image-enhancement technologies 
is improving by leaps and bounds.
NBI involves optical filters to narrow bandwidths 
of light; a novel system with ‘dual-focus’ function 
has recently been introduced. These new NBI 
systems focus more on mucosal tissue and capil-
lary network and the images appear to be brighter 
and clearer.
The new i-scan OE is a unique combination of 
optical and digital enhancement chromoendoscopy 
that improves vessel and mucosal pattern charac-
terization. It involves three types of algorithms: sur-
face enhancement (i-scan 1), tone enhancement 
(i-scan2) and optical enhancement (i-scan 3).
The BLI and LCI have been developed using 
LASEREO endoscopic system (Fujifilm, Japan), 
based on two monochromatic types of diode laser 
(410 and 450 nm) as the light source, and designed 
to be able to increase visibility of microvessels and 
mucosa. BLI images are produced by the combina-
tion of spectral and WLE that improve contrast 
imaging, while LCI expands colour range and 
enhances slight colour differences in the red region 
of the mucosa, resulting in more or less visible 
mucosal redness.66
In a recent study, 52 patients affected by UC 
underwent LCI endoscopic assessment with cor-
responding histology. LCI technology significantly 
improved the diagnosis of subtle inflammation 
and strongly correlated with Matts’ histopatho-
logical score. Interestingly, among areas with 
MES 0, 41.8% and 4.6% showed images of 
mucosa redness with visible vessels and redness 
without visible vessels, respectively. Moreover, 
non-relapse rates significantly correlated with LCI 
classification (p = 0.0055), but not with MES 
(p = 0.0632). So, LCI is a potential tool to better 
assess MH and inflammation in UC.67
Neumann and colleagues compared HD WLE 
with computed virtual chromoendoscopy i-scan 
to detect severity and extent of mucosal inflam-
mation in patients with mild or inactive IBD. 
They observed that i-scan significantly improved 
the prediction of extent and severity of disease 
compared with WLE.68
Recently, Sasanuma and colleagues showed the 
relationships between magnified NBI findings and 
histology for 52 patients affected by UC with MES 
0–1. There was a statistically significant relation-
ship between NBI findings and pathological find-
ings (p < 0.01). Mucosa, apparently healed, had 
different vascular patterns with NBI, and several 
vascular patterns reflected different risks of recur-
rence.69 Therefore, the vascular pattern in UC may 
distinguish stable from unstable MH.
A new EVC scoring system, the Paddington 
International Virtual Chromoendoscopy Score 
(PICaSSO) was developed using the i-scan platform 
and validated to better assess and grade inflamma-
tion, especially MH in UC. This score involved a 
more detailed classification of mucosal and vascular 
changes, reflecting acute and chronic inflammation 
and healing; it introduced the endoscopic findings of 
MH and vascular healing using EVC. It correlated 
with histological scores, including ECAP (extent, 
chronicity, activity, plus additional findings), a new 
histological scoring system that includes acute and 
also chronic inflammation, the Harpaz score and 
RHI. It can potentially distinguish clearly between 
absence and presence of mild inflammation.70,71
In addition, Iacucci and colleagues have demon-
strated in UC patients the close correlation 
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between i-scan OE magnification and histological 
scores RHI and ECAP. The overall i-scan OE 
score correlated with ECAP (r = 0.70; p < 0.001) 
and RHI (r = 0.61; p < 0.01). The accuracy to 
detect abnormalities by ECAP was 80% (sensitiv-
ity 78%, specificity 100%), while by RHI was 68% 
(sensitivity 78%, specificity 50%). Significantly, in 
approximately 31–41% of the patients with MES 
0, there was abnormal mucosal or vascular pat-
terns detected by i-scan OE.72 Table 1 presents a 
summary of the studies exploring the relationship 
between MH and histological healing.
Confocal laser endomicroscopy
Confocal laser endomicroscopy (CLE) provides in 
vivo histologic analysis. Due to its resolution and 
tissue penetration, CLE can describe microscopic 
imaging such as crypt alterations and microvascu-
lar changes. To obtain confocal images, contrast 
agents have to be administered systemically. The 
most widely used fluorescent agent is intravenous 
fluorescein sodium. Different devices are available; 
one of the most widely used currently is probe 
CLE (pCLE; Cellvizio, Mauna Kea).73
Several studies have assessed the ability of CLE 
to assess histologic degree and extension of 
mucosal inflammation in patients affected by 
IBD (Figure 1).59
One of the earliest pilot studies evaluated the mor-
phologic differences of the colonic mucosa between 
active and inactive UC. The crypts in UC patients 
with non-active disease were mainly small, round 
and slightly irregular in arrangement. In contrast, 
in active UC goblet cells were invisible, colonic 
crypts appeared large, variously shaped, irregularly 
arranged with numerous inflammatory cells and 
capillaries in the lamina propria.74 CLE also seems 
to be able to differentiate between UC and CD. In 
a prospective study involving 79 patients with IBD, 
Table 1. Relationship between mucosal healing (MH) and histological healing (HH).
Study Method Disease N patients Mucosal healing Histological healing Outcome
 Definition N (%) Index score N (%)  
Fernandez-
Blanco
et al.31
WL UC 34 Mayo 
score ⩽ 2
21 (62%) Geboes 
grade ⩽ 3.0
9 (26%) Cohen’s 
k = 0.293
Bryant et al.39 WL UC 91 Baron score 
⩽1
56 (61%) Truelove 
and 
Richards’ 
Index
47 (52%) κ = 0.56
(95% CI 0.36 to 
0.77)
Iacucci et al.62 i-scan UC 78 i-scan = 1 5 (6.4%) NYMS = 0 18 (78.3%) r = 0.65
(95%CI 0.49–
0.76) p < 0.0001
Uchiyama 
et al.67
LCI UC 193 
areasa
LCI A 50 (25.9%) Matts’ 
grade = 1
47 (24.4%) p = 0.001b
Sasanuma 
et al.69
NBI UC 52 BV-BB
BV-BH
41 (78%) Japanese 
Ministry 
of Health, 
Labour, and 
Welfare
n/a p < 0.01
Iacucci et al.72 OE UC 41 UC i-scan OE
mucosal 0–1
vascular 0–1
11 (26.8%)
8 (19.5%)
ECAP
RHI
n/a r = 0.70; 
p < 0.001
r = 0.61; p < 0.01
a50 patients, calculations are done on the number of areas.
bLCI index at each Matts’ histopathological grade; ANOVA linear contrast test.
ECAP, extent, chronicity, activity, plus additional findings; LCI, linked colour imaging; NBI, narrow-band imaging; NYMS, New York Mount Sinai 
system; OE, optical enhancement; RHI, Robarts Histological Index; UC, ulcerative colitis; WL, white light.
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a CLE scoring system was developed and poten-
tially allowed prediction of the diagnosis of IBD 
with high overall accuracy.75
Li and colleagues evaluated inflammatory activity 
in 73 UC patients and created a four-grade CLE 
classification system. All the parameters consid-
ered – crypt architecture, fluorescein leakage, 
microvasculature – had good correlation with his-
topathology. Interestingly, more than half of 
patients with normal mucosa seen on conventional 
WLE showed acute inflammation on histology, 
whereas no patients with normal mucosa seen on 
CLE showed acute inflammation on histology.76
Preliminary results provided by Iacucci and col-
leagues of a prospective study involving 82 UC 
patients have shown the ability of PICaSSO and 
the pCLE grading system to predict histological 
healing assessed by RHI. A PICaSSO of ⩽4 and 
pCLE of ⩽10 predicted histological healing at 
RHI ⩽6, with accuracy of 92.7% (95% CI, 84.8–
97.3) and 95.1% (95% CI, 88.0–98.7), respec-
tively. Of note, PICaSSO score and pCLE score 
can accurately predict histological healing, 
defined by RH, better than MES, which had an 
accuracy of 84.2% (95% CI, 74.4–91.3).77
The ability of pCLE to predict disease relapse and 
clinical outcome was first assessed by Kiesslich 
and colleagues. They have observed a direct visu-
alization of local epithelial barrier defects at sites 
of cell shedding in patients with IBD in remis-
sion.78 Whether such barrier defects predispose to 
relapse requires further prospective studies.
Buda and colleagues composed an outcome score 
by pCLE, combining fluorescence and crypt 
diameter (p < 0.01), able to predict disease flare 
during a 12-month follow-up period in patients 
affected by long-standing UC. ROC analysis 
revealed that a pericrypt fluorescence >3100 pix-
els and a crypt diameter >90 μm increased sig-
nificantly the probability of disease relapse.79
Karstensen and colleagues, in a longitudinal study 
involving UC patients, showed how endomicro-
scopic features (fluorescein leakage, micro-erosion, 
crypt tortuosity, crypt openings, density and vascular 
alteration, inflammatory infiltrate) could change 
before and after escalation of therapy and their cor-
relation with endoscopic and histopathologic 
changes. After intensification of therapy, an improve-
ment of abnormal colonic crypt architecture involv-
ing modifications in crypt tortuosity, distorted crypt 
Figure 1. (a–c) Endoscopic images of mucosal healing (normal vascular and mucosal pattern) with i-scan 
OE (optical enhancement). (d,e) Regular crypts and normal vessels with confocal (fluorescein 2.5 ml 10%). (f) 
Haematoxylin–eosin, original magnification ×200 showed colonic mucosa healing. (g) Haematoxylin–eosin, 
original magnification ×400.
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lumen and decreased crypt density was detectable 
by CLE. All of these features were significantly cor-
related with the Geboes Histology Index.80
Tontini and colleagues have evaluated, in a pro-
spective, multicentre, observational study, the abil-
ity of CLE to predict long-term clinical course in 
49 CD patients. They identified two main hall-
marks of active inflammation by CLE – focal cryp-
titis and crypt architecture abnormality – and 
evaluated the role of CLE, CRP, Crohn’s Disease 
Activity Index (CDAI), and Crohn’s Disease 
Endoscopic Index of Severity (CDEIS) to predict 
hospitalization, surgery and escalation treatment in 
a follow-up period of 4 years. At 1-year follow-up 
there was a significantly high risk of medical treat-
ment escalation (p < 0.001; RR = 2.61; positive 
likelihood ratio = 3.27), and transmural adverse 
events (p = 0.025; RR = 4.06; positive likelihood 
ratio = 1.7) in the presence of endoscopic cryptitis 
and crypt architecture abnormality by CLE.81
Recently, Hundorfean and colleagues have pro-
posed an endomicroscopic MH score for UC 
(eMHs) based on CLE imaging. eMHs had a 
good correlation with the histological score 
(Gupta Index) and MES. After 3 years, the eMHs 
responder patients had an overall reduced need 
for corticosteroids, lower hospitalization rates 
and a higher surgery-free survival as compared 
with eMHs non-responders. eMHs was more 
accurate than endoscopic, histologic and clinical 
scores for predicting clinical outcomes.82
Molecular imaging with fluorescent antibodies and 
CLE are a new tool that can be useful to precisely 
stratify therapy and predict therapeutic responses, 
enhancing personalized therapy.83 Despite these 
promising results, standardization of practice, 
training programmes and more prospective valida-
tion studies involving a larger population are essen-
tial before their introduction into clinical practice.
Endocytoscopy
Endocytoscopy (EC) is a high-resolution and 
high-magnification endoscopic technique that 
allows real-time observation of cells and nuclei at 
the mucosal surface during ongoing endoscopy in 
vivo (Figure 2).
Figure 2. (a,b) Endoscopic images of mucosal healing (normal vascular and mucosal pattern) with 
high-definition and narrow-band imaging. (c) Honeycomb appearance of the colonic mucosa with dye 
chromoendoscopy (methylene blue 0.2%) and Magni view. (d,e) Endocytoscope (methylene blue 0.2%) showed 
regular crypts and normal spaces between the crypts. (f) Haematoxylin–eosin, original magnification ×200 
revealed colonic mucosal healing. (g) Haematoxylin–eosin, original magnification ×400.
OM Nardone, R Cannatelli et al.
journals.sagepub.com/home/tag 11
Bessho and colleagues, in a pioneering study, 
have investigated the potential role of EC system 
score (ECSS) to assess histological disease activ-
ity. These authors developed a UC scoring sys-
tem based on the shape of crypts, the distance 
between neighbouring crypts and the visibility of 
superﬁcial microvessels. The ECSS score had a 
good correlation with Matts’ histopathological 
grade and so it could be a good predictor of histo-
pathological activity in UC.84
Similarly, Nakazato and colleagues have shown 
the diagnostic accuracy of ECSS to determine his-
tological remission in 64 UC patients with endo-
scopic remission MES 0. The ECSS showed high 
accuracy to detect histological remission, with a 
sensitivity of 0.77 (95% CI, 0.59–0.89), a specific-
ity of 0.97 (95% CI, 0.83–0.99) and a diagnostic 
accuracy of 0.86 (95% CI, 0.75–0.93).85
Neumann and colleagues have determined the 
role of EC for discriminating inflammatory cells in 
40 patients with IBD. The concordance between 
EC and histopathology for grading intestinal dis-
ease activity was 100%. EC was also able to distin-
guish different histopathological features, which is 
the strength of this endoscopic technology.86
Recent data have evaluated the role of EC in pre-
dicting histology and clinical outcome. Ueda and 
colleagues reported on the correlation between 
ECSS and MES for mild-to-moderate UC 
patients. A simple grading system of four types, 
depending on the alterations in crypt microstruc-
tures (shape of crypts, distance between crypts 
and small vessels in rectal mucosa of UC patients) 
has been proposed and was significantly associ-
ated with microscopic features. Moreover, there 
were significant differences in remission rate 
according to EC classification: deformed pits with 
distorted crypt lumen, unordered arrangement 
and disruptive or disappeared pits have higher 
recurrence rates.87 Table 2 summarizes the stud-
ies exploring the correlation between new 
advanced endoscopic techniques and histology.
Finally, there is an emerging attention to the 
 ability of artificial intelligence (AI) system to 
improve the performance of gastrointestinal 
endoscopy.88 Exciting data have been reported 
concerning the feasibility of AI differentiating 
neoplastic  colorectal polyps (adenoma) from 
non-neoplastic polyps.89–91 A computer-aided 
diagnosis (CAD) system could play a potential 
role also in IBD to reduce the need for biopsy and 
to classify surface and vascular pattern morphol-
ogy accurately.
Recently, Maeda and colleagues have shown that 
CAD using EC had a good diagnostic ability to 
differentiate histologically active versus histologi-
cal healing in UC. A total of 187 patients were 
enrolled and retrospectively followed. First, they 
underwent conventional WLE to determine the 
area most severely inflamed, according to MES, 
and then EC was performed. A comparison 
between CAD, inflammatory activity with MES 
0–1 and histologic inflammatory activity per 
patient was performed. CAD had a sensitivity of 
74%, specificity of 97% and accuracy of 91% to 
predict histological inflammation; its reproduci-
bility was perfect (κ = 1).92
More studies are needed to validate the role of the 
use of EC combined with AI to grade inflammation 
and predict clinical outcome in IBD. It is likely that 
EC can help in characterizing  subtle dysplastic 
lesions better with its high magnification.
Future of assessment of mucosal healing by 
advanced endoscopy at the horizon
The development and validation of new endo-
scopic imaging techniques promise to provide 
new and more precise tools to identify MH and 
distinguish from subtle mucosal inflammation. 
These tools have to meaningfully relate to clinical 
outcome measures in the short and medium term 
and may radically change the ways we interpret 
MH, not just as absence of inflammation but as 
an active process of healing. Regenerative changes 
may ‘mimic’ inflammation and its distinctive fea-
tures need to be recognized. Many studies have 
shown that macroscopic healing determined by 
WLE may not be sufficient to accurately predict 
long-term disease outcomes, as it often does not 
correlate with histological remission. Therefore, 
histological healing is becoming one of the targets 
needed to achieve tight control and better clinical 
outcome for patients with IBD, especially UC. 
However, clear evidence regarding benefits for 
optimization and escalation of therapy based on 
histological activity is still lacking. Growing data 
have also demonstrated that, in the future, intes-
tinal tissue levels of anti-TNF agents will play a 
key role in deciding on treatment withdrawal. 
Indeed, the normalization of mucosal gene 
expression levels of TNF in CD and recently in 
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UC were a predictor of sustained, long-term 
remission following discontinuation of infliximab 
therapy.93–95 It is expected that these new data 
will have a significant impact on future exit strate-
gies for IBD patients. Colonic mucosal transcrip-
tomic changes in long-duration UC may reflect 
colitis-associated cancer pathways, but future 
studies are needed to understand whether such 
changes identify high-risk patients for dysplasia 
compared to MH.96
Novel emerging endoscopic techniques can better 
assess MH, correlate with histology and therefore 
may better predict clinical outcome. These can 
help to direct precisely targeted biopsies, espe-
cially when there is patchy inflammation and 
healing. In the future, they can accurately manage 
therapy, as escalation or exit strategies, and pro-
mote personalized therapy. Close interaction is 
required between endoscopists and pathologists 
to achieve these ambitious goals.
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Table 2. Correlation between new advanced endoscopic techniques and histology.
Study Disease N patient Technique Histological 
index
Endomicroscopy findings Outcome
Li et al.76 UC 73 CLE Geboes Index Crypt architecture, fluorescein leakage, 
microvascular alteration
p < 0.001a
Karstensen 
et al.80
UC 22 CLE Geboes Index Fluorescein leakage, micro-erosions, 
crypt tortuosity, crypt openings, crypt 
density, inflammatory infiltrates
p < 0.001b
Hundorfean 
et al.82
UC 23 CLE Gupta score Crypt number, lumen leakage and 
perivascular leakage
rs = 0.82,c
p < 0.0001
Bessho 
et al.84
UC 55 EC Matt’s score Shape of crypts, distance between 
neighbouring crypts and visibility of 
superﬁcial microvessels
r = 0.713,b 
p < 0.001
Nakazato 
et al.85
UC 64 EC Geboes Index <2 Shape of the crypts,
distance between neighbouring crypts, 
visibility of
superficial microvessels
κ = 0.72
Neumann 
et al.86
IBD 40 pEC Riley Neutrophils, basophiles, eosinophilic 
granulocytes and lymphocytes.
κ = 0.81–1.00
Ueda et al.87 UC 32 EC Severe mucosal 
inflammation, 
crypt abscess, 
goblet cell 
depletion
Regular arrangement of round to oval 
pits, irregular arrangement with/without
enlarged spaces between regular pits, 
deformed pits with distorted crypt 
lumen, disruptive or
disappeared pits.
p < 0.0005d
p < 0.01
p < 0.001
aSpearman’s rho correlation and ANOVA, p < 0.01 was considered statistically significant.
bSpearman rank test.
cPearson’s correlation.
dp < 0.05 was considered statistically significant.
CLE, confocal laser endomicroscopy; EC, endocytoscopy; IBD, inflammatory bowel disease; pEC, probe endocytoscopy; UC, ulcerative colitis.
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